Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 27, 2025 08:01 ET | Source: XOMA Royalty Corporation; BioInvent

XOMA Royalty Purchases Mezagitamab Royalty and Milestone Rights Held by BioInvent International for up to USD $30 Million

XOMA Royalty acquires mezagitamab economics from BioInvent